english.prescrire.org > Topics > Advancing healthcare policy > The Medicines in Europe Forum: actions by the network > Actions in 2008-2010 > EMEA transparency policy falls short: a weak and irresponsible project (9/2009)

Advancing healthcare policy

The Medicines in Europe Forum: actions by the network

Advancing healthcare policy

Selected actions by the Medicines in Europe Forum in 2008-2010
EMEA transparency policy falls short: a weak and irresponsible project Joint Answer to EMEA Consultation, (September 2009)

In their anwer to European Medicines Agency (EMEA)'s public consultation, Prescrire and its allies find EMEA's draft transparency policy to be weak and irresponsible. They call for EMEA's full accountability to the public. Real transparency is an indispensable prerequisite to restore EU citizens’ confidence in EMEA’s decisions.

© September 2009

> Click here for the full document "EMEA transparency policy falls short: a weak and irresponsible project", a joint answer by HAI Europe, ISDB and MiEF to "The EMEA transparency policy – draft for public consultation" (pdf, 382 Ko).

Overview
Actions in 2017

Health technology assessment: joint response to the EU Commission Consultation (1/2017)

Actions in 2016

Open letter to the EC on "Strengthening the Balance in the Pharmaceutical Systems" (9/2016)
Member States ought to support the EU Presidency's vision on access to affordable medicines (4/2016)
Trilogue Meetings: increase transparency to level the playing field (3/2016)
Representatives of civil society call for an R&D framework driven by global public health needs (2/2016)
Why You Should Be Concerned About TTIP and Access to Medicines (2/2016)

Actions in 2015

A PRIME example of how EMA is pushing for accelerated market approvals, but at what cost for patients? (12/2015)
European medicines agencies must address independence and transparency problems (7/2015)
EU directive on trade secrets: amendments needed! (3/2015)
EU Clinical Trials Regulation: EMA steers away from transparency (2/2015)
European Directive on trade secrets: A threat to access to public health data (2/2015)

Actions in 2014

EU trade secrets directive: statement by a multi-sectoral NGO coalition (12/2014)
EMA softens its conflict of interest policy (11/2014)
EMA's final policy on access to clinical data (10/2014)
EU Pharmacovigilance public hearings (10/2014)
Clinical trials regulation: a major advance in transparency (9/2014)
INNs of biologics and biosimilars: consistency must be preserved (9/2014)
A step backwards on pharmaceutical policy at the EU Commission (9/2014)
EMA's policy on pharmacovigilance data (9/2014)
Providing "scientific advice" to pharma industry undermines the independence of regulatory authorities (7/2014)
'Investor-to-state dispute settlement' in EU–US trade deal threatens access to affordable medicines (7/2014)
EMA's new policy on access to clinical data (6/2014)
Backpedalling on EMA’s "proactive publication of clinical-data" draft policy (5/2014)
The US-EU Trade Agreement Proposals by the pharmaceutical industry undermine European public policy making and public health (3/2014)
EU Regulation on clinical trials: close to the finish line (3/2014)

Actions in 2013

"Biosimilars": the EMA makes a timid shift towards a more pragmatic approach (10/2013)
Medical devices legislation: regaining the trust of European citizens (5/2013)
Amended proposal for a new directive on transparency measures regulating the prices of medicinal products: still threatening Member States' health systems (4/2013)
Clinical trials regulation: choose transparency! (4/2013)
New proposal for a Regulation on clinical trials: Protect human subjects; Strengthen citizens' right to information (2/2013)

Actions in 2012

French sunshine act: is the French government backing down on industry gifts? (10/2012)
Medical devices: an entire overhaul of the medical legislation is needed (10/2012)
European Medicines Agency and pharmacovigilance: no to a fee-for-service system (9/2012)
Black triangle for medicines: Positive move but poor implementation plan (8/2012)
Proposal for a new Directive on transparency of measures regulating the prices of medicinal products: EC oversteps its role (7/2012)
Access to EU's documents is essential (6/2012)
EU Parliament says no and no again to EMA (5/2012)
Fighting "counterfeit medicines" should not be used as a pretext to track sales data (4/2012)

Actions in 2011

Revised proposals on "information" to patients: Still an open door to advertising (10/2011)
Response to HMA/EMA on identification of commercially confidential information (8/2011)
Packaging for non-prescription medicines: Prescrire's response to EMA (6/2011)
EMA suggestions on comparative clinical trials fall back behind ethical and scientific standards (3/2011)

Actions in 2008-2010

Final proposals on pharmacovigilance: Some progress, but a missed opportunity (12/2010)
Towards DTC advertising for prescription drugs? The autumn will be crucial (continued) (11/2010)
Towards DTC advertising of prescription drugs in Europe? (7/2010)
EMA's policy on conflict of interest: improvements needed (6/2010)
EMA road map: independence should be the priority (4/2010)
DTC Communication? Europeans deserve better (3/2010)
Medicines placed under the DG-SANCO’s competence (12/09)
EU Commission's proposals endanger the population (10/2009)
Future Commission: need for change in health goods governance (10/09)
EMEA transparency policy falls short: a weak and irresponsible project (9/2009)
EU Commission's proposals on pharmacovigilance dismantle the entire system (6/2009)
Legal proposals on "information" to patients by pharmaceutical companies (3/09)
Pharmaceutical package: a short-sighted vision that puts patients at risk (3/2009)
Joint open letter on the "Pharmaceutical Package" (11/08)
Recast of Medical Devices Directives (7/08)
"Patient information" by pharmaceutical companies: unanimous opposition (6/08)
Pharmacovigilance : overwhelming opposition to the EC proposals (5/2008)
Time to act for Patient Safety (5/08)
EC's "Information" proposal serves firms, not patients (4/08)
New European pharmacovigilance legislation: getting it right (2/08)

Actions in 2005-2007

EC puts companies before public health (7/07)
Pharmaceutical Forum's working group: a sham consultation (5/07)
Joint Declaration "Relevant information for citizens" (12/06)
Advanced therapy medicinal products (4/06)
Draft regulation on medicines for paediatric use (7/05)
Medicines for paediatric use: take the time to improve an important project (5/05)
Medicines for paediatric use (1/05)

The 2002-2004 campaign
About the MiEF
Back to the list of themes

Advancing healthcare policy

The Medicines in Europe Forum: actions by the network

Advancing healthcare policy

Selected actions by the Medicines in Europe Forum in 2008-2010 EMEA transparency policy falls short: a weak and irresponsible project Joint Answer to EMEA Consultation, (September 2009)

Selected actions by the Medicines in Europe Forum in 2008-2010
EMEA transparency policy falls short: a weak and irresponsible project Joint Answer to EMEA Consultation, (September 2009)